FTSE 100 held back by AstraZeneca trial setback
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
A trial setback for AstraZeneca has had a negative impact on the company's stock market value. This development has also affected the FTSE 100, holding it back. The extent of the impact on the FTSE 100 and AstraZeneca's value is reported, with the company's stock market value reportedly slumping by more than £20bn.